- Home
- PCYO vs CLLS Comparison
PCYO vs CLLS Comparison
Compare PCYO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- CLLS
- Stock Information
- Founded
- PCYO 1976
- CLLS 1999
- Country
- PCYO United States
- CLLS France
- Employees
- PCYO N/A
- CLLS N/A
- Industry
- PCYO Water Supply
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- PCYO Utilities
- CLLS Health Care
- Exchange
- PCYO Nasdaq
- CLLS Nasdaq
- Market Cap
- PCYO 248.0M
- CLLS 143.4M
- IPO Year
- PCYO N/A
- CLLS 2007
- Fundamental
- Price
- PCYO $10.05
- CLLS $2.11
- Analyst Decision
- PCYO
- CLLS Buy
- Analyst Count
- PCYO 0
- CLLS 1
- Target Price
- PCYO N/A
- CLLS $4.00
- AVG Volume (30 Days)
- PCYO 46.4K
- CLLS 109.9K
- Earning Date
- PCYO 07-09-2025
- CLLS 08-05-2025
- Dividend Yield
- PCYO N/A
- CLLS N/A
- EPS Growth
- PCYO 123.89
- CLLS N/A
- EPS
- PCYO 0.56
- CLLS N/A
- Revenue
- PCYO $27,447,000.00
- CLLS $54,747,000.00
- Revenue This Year
- PCYO N/A
- CLLS $48.52
- Revenue Next Year
- PCYO N/A
- CLLS $5.17
- P/E Ratio
- PCYO $18.00
- CLLS N/A
- Revenue Growth
- PCYO 40.36
- CLLS 351.26
- 52 Week Low
- PCYO $9.49
- CLLS $1.10
- 52 Week High
- PCYO $14.63
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- PCYO 42.81
- CLLS 81.31
- Support Level
- PCYO $10.00
- CLLS $1.56
- Resistance Level
- PCYO $10.96
- CLLS $1.49
- Average True Range (ATR)
- PCYO 0.34
- CLLS 0.14
- MACD
- PCYO -0.07
- CLLS 0.07
- Stochastic Oscillator
- PCYO 14.66
- CLLS 85.72
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.